Compare
Repligen Corp vs BioCryst Pharmaceuticals Inc vs ADMA Biologics, Inc. vs Twist Bioscience Corp
| Latest fiscal year | Repligen Corp RGEN | BioCryst Pharmaceuticals Inc BCRX | ADMA Biologics, Inc. ADMA | Twist Bioscience Corp TWST |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-09-30 |
| Revenue | $738.26M | $874.84M | $510.17M | $459.43M |
| Revenue growth (YoY) | +16.4% | +94.1% | +19.6% | +22.0% |
| Gross margin | 52.3% (computed) | n/a | 57.4% | 52.4% (computed) |
| Operating margin | 7.5% | 39.0% | 37.5% | -30.4% |
| Net margin | 6.6% | 30.2% | 28.8% | -28.3% |
| Net income | $48.89M | $263.86M | $146.93M | -$130.20M |
| EPS (Diluted) | $0.86 | $1.21 | $0.60 | -$2.08 |
| Operating cash flow | $117.42M | $347.37M | $50.40M | -$41.43M |
| Free cash flow | $93.90M | $344.90M | $27.82M | -$89.01M |
| Cash & equivalents | $566.02M | $89.74M | $87.63M | $533.99M |
| Total assets | $2.95B | $514.16M | $624.24M | $1.12B |
| Total liabilities | $843.57M | $633.31M | $146.92M | $233.79M |
| Shareholders' equity | $2.11B | -$119.15M | $477.32M | $888.02M |
| Return on year-end equity | 2.3% | n/a | 30.8% | -14.7% |
| Shares outstanding | 56.33M | 213.06M | 237.87M | 67.81M |
Revenue, most recent five fiscal years
| Fiscal year | Repligen Corp | BioCryst Pharmaceuticals Inc | ADMA Biologics, Inc. | Twist Bioscience Corp |
|---|---|---|---|---|
| Latest | $738.26M Ended 2025-12-31 | $874.84M Ended 2025-12-31 | $510.17M Ended 2025-12-31 | $459.43M Ended 2026-09-30 |
| 1 year earlier | $634.44M Ended 2024-12-31 | $450.71M Ended 2024-12-31 | $426.45M Ended 2024-12-31 | $376.57M Ended 2025-09-30 |
| 2 years earlier | $632.36M Ended 2023-12-31 | $331.41M Ended 2023-12-31 | $258.21M Ended 2023-12-31 | $312.97M Ended 2024-09-30 |
| 3 years earlier | $801.54M Ended 2022-12-31 | $270.83M Ended 2022-12-31 | $154.08M Ended 2022-12-31 | $245.11M Ended 2023-09-30 |
| 4 years earlier | $670.53M Ended 2021-12-31 | $157.17M Ended 2021-12-31 | $80.94M Ended 2021-12-31 | $203.56M Ended 2022-09-30 |